Formycon AG (FSB: FYB, Prime Standard) announced it will publish its financial results for the 2025 fiscal year on April 22, 2026. The Management Board will discuss the company's development, key financial figures, and provide an outlook for the 2026 fiscal year during a conference call on the same day at 3:00 PM (CEST). The call will be broadcast live in English and can be accessed via registration at this link. After registration, participants will receive a confirmation email with dial-in details. The presentation and audio broadcast will be available through the webcast link at https://www.webcast-eqs.com/formycon-2025-fy. Following a brief presentation, the Management Board will take questions from analysts. The conference call will be recorded and later accessible on Formycon's website at https://www.formycon.com/en/investor-relations/publications/.
This announcement matters because it signals Formycon's continued engagement with the investment community amid a pivotal period for the biosimilars market. With two biosimilars already on the market—FYB201/ranibizumab and FYB202/ustekinumab—and another, FYB203/aflibercept, approved by the FDA, EMA, and MHRA, the company is poised to capitalize on the growing demand for affordable biopharmaceuticals. The outlook for FY 2026 will be closely watched, especially as four pipeline candidates, including FYB208/dupilumab, are in development. The biosimilars market is projected to grow from around $21 billion to over $74 billion by 2030, and Formycon's progress could significantly impact patient access and healthcare costs.
Formycon also announced its participation in several investor conferences in the second quarter of 2026. On May 11–12, CFO Enno Spillner will attend the Equity Forum Spring Conference in Frankfurt, Germany. On May 28, the company will publish its first quarter 2026 results, followed by a conference call with CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl. From June 2–4, CFO Spillner will represent Formycon at the Jefferies Global Healthcare Conference in New York City. On June 8, the management team will participate in the mwb research Roundtable via webcast. The Annual General Meeting is scheduled for June 10 in Munich, and on June 18, CFO Spillner will attend the UBS Life Sciences Conference in London. A full financial calendar is available at https://www.formycon.com/en/investors/financial-calendar/.
These conferences provide a platform for Formycon to present its strategy and pipeline to global investors. The company's focus on biosimilars in ophthalmology, immunology, and immuno-oncology addresses major therapeutic areas with high unmet needs. By leveraging partnerships for commercialization, Formycon aims to expand access to cost-effective biologics. The upcoming results and investor interactions will be crucial for assessing the company's financial health and growth trajectory in a competitive landscape where patent expirations on blockbuster biologics are creating opportunities.
